L
ung cancer is one of the most common malignancies in the world. 1 In Singapore, it is the most frequent cancer in men, and ranks third most common in women. 2 The prognosis of lung cancer is poor, with a 5-year overall survival rate of approximately 15%. 3 The combination of high incidence with high lethality makes lung cancer the leading cause of cancer deaths in both men and women in many countries, including United States 4 and Singapore. 2 Smoking is the most important risk factor for lung cancer, as supported by epidemiologic evidence since the 1950s. 5, 6 It was estimated that approximately 85% of lung cancer cases were attributed to smoking. 7, 8 Most of these studies were done in Western countries and among male patients with lung cancer worldwide. Data from Asian popula-tions, especially among female patients with lung cancer, indicate that other risk factors are as important, as smoking alone cannot explain the epidemiologic characteristics of lung cancer seen in some
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Asian countries. In these countries, the incidence of smoking is low among women; yet, there is a relatively high incidence of lung cancer among them. 9 -12 The contribution of other biological, environmental, occupational, and socioeconomic factors may be more important in a population with high lung cancer incidence but low attributable risk from smoking. 13 Smoking increases the risk of all histologic subtypes of lung cancer, although the relative risk is greater for squamous cell and small cell carcinoma than for adenocarcinoma. 14 There is an increasing rate of adenocarcinoma and decreasing incidence of squamous cell carcinoma reported in men in United States 15 and Europe. 16 Among the nonsmokers and the women, adenocarcinoma is most frequently observed. 17 Based on the observation that there are differences in epidemiologic characteristics and histologic subtypes between smokers and nonsmokers with non-small cell lung cancer (NSCLC), it is reasonable to assume that there would be underlying biological differences between the two groups. In fact, studies 18, 19 have identified significant differences in the mutational frequencies and spectra in lung cancers between smokers and nonsmokers that suggest different molecular carcinogenic pathways are involved in their development. Since the tumor biology is different, it is possible that this could translate into differences in survival and response to chemotherapy between the two groups. We performed a retrospective analysis of patients with NSCLC seen during the period of January 1999 until August 2002, to investigate the impact of the smoking status of patients on the behavior of the disease with regards to survival outcome and response to chemotherapy.
Materials and Methods
This study was conducted at the Department of Medical Oncology, National Cancer Center, a tertiary referral center in Singapore that is accessible to patients from all socioeconomic status. The case records of patients with NSCLC diagnosed during the period of January 1999 until August 2002 were retrieved. Selected epidemiologic characteristics, treatment given, and response to chemotherapy were recorded. Smoking history was taken as recorded in the case records by the attending physician. Smoking status was classified as defined by the World Health Organization classification criteria for smoking. 20 A nonsmoker was defined as one who had never smoked before or smoked too little in the past to be regarded as an ex-smoker.
Overall survival for each patient was measured from the date of diagnosis until the date of death, or until the date the patient was last known to be alive for censored observation. The data were checked with the Singapore registry of births and deaths on December 31, 2002 . It is mandatory for Singapore residents to register in the event of death; therefore, the mortality data for residents is complete and exhaustive.
Response to chemotherapy was defined in accordance to World Health Organization criteria. 21 Complete response refers to complete disappearance of all measurable and evaluable disease with no new lesions, and partial response refers to a Ն 50% decrease in the sum of the products of perpendicular diameters of measurable lesions. Stable disease is defined by Ͻ 50% reduction or Ͻ 25% increase in the measurable disease. Progressive disease refers to an increase in measurable disease by Ͼ 25% or the appearance of new lesions.
The duration of response was measured from the time of first documentation of complete response, partial response, or stable disease until the first date that progressive disease was objectively documented. If progression was not observed or the patient was unavailable for follow-up, the duration was measured from the date of complete response, partial response, or stable disease until the date of last follow-up.
Statistical Analysis
2 test was used to test for differences in gender, race, histologic subtype, performance status (as defined by Eastern Cooperative Oncology Group [ECOG] classification), American Joint Committee on Cancer (AJCC) stage, comorbidities, and weight loss between the smokers and nonsmokers. The difference in age at diagnosis between the two groups was compared using a t test.
A log-rank test was used to compare the overall survival between smokers and nonsmokers, and Kaplan-Meier survival estimates and curves were obtained. A Cox proportional hazards model was later used to adjust for known prognostic factors including ECOG status, presence of weight loss, AJCC stage at diagnosis, and treatment received.
The type of chemotherapy and response to first-line chemotherapy between smokers and nonsmokers among patients with AJCC stage IIIB or IV disease were compared using a 2 test. Kaplan-Meier estimates of response duration to first line chemotherapy were obtained and compared using a log-rank test.
Results

Patient Characteristics
A total of 317 patients with NSCLC were identified and analyzed (Table 1) . At the time of analysis, 187 patients (59.0%) had died. There were 202 smokers (63.7%) and 115 nonsmokers (36.3%). The majority of them had advanced disease, as expected in a population of patients referred to the Department of Medical Oncology. There were significantly more male patients and squamous cell carcinoma among the smokers, while the proportion of female patients and adenocarcinoma was higher among the nonsmokers. A higher percentage of smokers reported weight loss and had poorer performance status compared to the nonsmokers, although the difference was not statistically significant. Diagnoses were made in nonsmokers almost a decade earlier than the smokers (mean age difference, Ϫ 7.94 years; 95% confidence interval [CI], Ϫ10.7 to Ϫ5.18; p Ͻ 0.001).
Survival Data
The median survival for all patients was 15.2 months (95% CI, 12.1 to 18.2). Figure 1 shows the Kaplan-Meier survival curves for smokers and nonsmokers, log-rank p ϭ 0.14. Nonsmokers had a median survival of 18.5 months, while smokers had a median survival of 13.6 months. When known prognostic factors including ECOG status, presence of weight loss, stage at diagnosis, and treatment received were taken into account using a Cox proportional hazards model (Table 2) , there was no statistically significant difference between smokers and nonsmokers (hazards ratio, 0.98; p ϭ 0.92). However, performance status, weight loss, stage at diagnosis, and treatment with chemotherapy were factors that independently predicted for survival outcome. These findings concur with previous studies. 22, 23 In addition to these prognostic factors, comorbidities, histologic subtype, gender, and age at diagnosis were later included in the model using a stepwise selection procedure. Only age at diagnosis was statistically significant. Every 10-year increase in age resulted in approximately a 30% increase in hazard. The hazard ratio estimates for the other prognostic factors remained similar (results not shown).
Response to Chemotherapy
Two hundred thirty-one patients had AJCC stage IIIB and IV disease. Eighty-five patients (36.8%) did not receive chemotherapy, while 146 patients (63.2%) were treated with palliative intent. The percentage of smokers and nonsmokers who received palliative chemotherapy was 57.9% and 68.6%, respectively (Table 3 ). There was no statistically significant difference in the chemotherapy regimens administered between the two groups There was no significant difference in the response to first-line chemotherapy in the two groups (p ϭ 1.0). Association of histologic subtype, weight loss, gender, age, and stage at diagnosis with response to chemotherapy was investigated using a logistic regression model (results not shown). None of these were found to be significant. Response between smokers and nonsmokers remained similar after adjusting for these factors. The duration of response to chemotherapy was also similar between these two groups (p ϭ 0.145).
Discussion
The smoking prevalence rates in our resident population are 26.9% for male subjects and 3.1% for female subjects, 24 and this rate among the female subjects is much lower compared to that in the United States. 25 The standardized adjusted rate for lung cancer in female subjects in Singapore is among the highest in the Southeast Asian countries, 26 but paradoxically the smoking rate is among the lowest. This is confirmed in our study, in which the percentage of patients with NSCLC who were nonsmokers was 36.3%, which is higher than that seen in Western countries. 8 In addition, among the nonsmokers, 73.9% were women and 75% had adenocarcinoma. The high incidence of female nonsmokers with adenocarcinoma is often seen only in the Asian population. 17 The possible etiologic factors and risk factors are still largely unknown, and this is a relatively unexplored area of research. Several studies 27, 28 in the Chinese population have suggested exposure to oil fumes during cooking as a significant factor among nonsmokers with lung cancer, but this remains to be proven.
One can postulate that passive smoking may be a contributory factor. Exposure to environmental tobacco smoke is difficult to quantify objectively, and therefore is subject to self-reported estimates, which are not accurate. 29 Similarly, we believed that the documentation of passive smoking was not adequately reflected in our data, and this aspect was thus not addressed. An important observation in our study that may argue against passive smoking as a significant factor is that the mean age at diagnosis for nonsmokers was almost a decade earlier compared to the smokers. It is known that there is a clear dose-response relation between smoking and lung cancer, in which the risk increases with the number of cigarettes smoked, years of smoking, and earlier age at onset of smoking. 30 Patients exposed to passive smoke would have a lower amount of carcinogen compared to the active smokers and should, by inference, acquire lung cancer later. Our counterintuitive observation was also corroborated by a similar observation in one other epidemiologic study, 17 in which the authors showed that the mean age at which nonsmokers succumb to lung cancer was younger than that among smokers in Asian countries like Japan and Hong Kong. However, one could also postulate that this subset of the population is constitutionally more susceptible to environmental carcinogenic effects, including that from passive smoking that resulted in the earlier onset of the cancer manifestation. It is possible that the interplay of the genetic make-up controlling carcinogen-metabolizing enzymes and the DNA repair capability could play a significant part, and further research along this aspect may help to delineate those who are at risk.
Chemotherapy has been shown to improve survival in advanced lung cancer compared to best supportive care. 31 Our study shows that the use of chemotherapy is an independent predictor of improved survival, which is in line with previous studies. 23, 32 However, no significant differences in survival, response rate, and duration of response to chemotherapy between smokers and nonsmokers could be observed. Cytotoxics kill cancer cells in a nonselective manner, in that they do not target specific molecular pathway(s) driving and maintaining the carcinogenic process. Hence, it can be difficult to appreciate the impact of any mutational differences between these two groups of patients with the use of chemotherapy. In smokers with lung cancer, p53 mutations were detected more often compared to nonsmokers, 33 and there is also a predominance of p53 G3 T transversion that reflects mutagenic changes in DNA caused by tobacco smoke. K-ras mutations in lung cancer are also reported to be more frequent in smokers than in nonsmokers. 34 Comparative genomic hybridization analysis of adenocarcinoma from nonsmokers in one study 35 identified a distinct aberration at chromosome 16p in these tumors. It is likely that a more targeted form of treatment that inhibit the predominant pathway(s) that initiate and maintain the carcinogenic process may make this biological difference between tobacco-induced and non-tobaccoinduced lung cancer more manifest. Gefitinib, a tyrosine kinase inhibitor, is one such possible example. 36 Already, there are studies 37, 38 that show the subgroup of patients who were nonsmokers and had adenocarcinoma respond better to gefitinib.
We had postulated that there could be differences in survival and response to chemotherapy between smokers and nonsmokers based on the well-established different mutational spectrum, but this was not borne out by our study. It is possible that the sample size is not large enough to show the difference. However, it is also likely that other clinical factors such as performance status, presence of weight loss, and the use of chemotherapy proved to be more significant, thereby masking the impact of smoking status. The other possible explanation is that lung cancers arising as a result of tobacco smoke exposure or otherwise are equally aggressive in behavior, which is independent of the carcinogenesis pathways driving the process, and hence will have similar survival outcome.
Conclusion
Our study has demonstrated that there are differences in epidemiologic characteristics and histologic subtypes between smokers and nonsmokers with NSCLC. The lack of observable differences in response to chemotherapy and survival outcome between these two groups may imply that currently available cytotoxics have no impact on the biological differences that may exist. The advent of targeted therapeutics may make this difference more obvious in future. It must be emphasized, however, that this study was limited mainly to patients with advanced disease who received palliative treatment. Hence, we recognize that the findings of this study may not reflect the situation in those with earlier stages and more curable disease. We hope to include all stages for our future studies, especially those subjected to surgery for curative intent. It is also imperative that more studies be conducted to further delineate and characterize the differences between these two etiologically different forms of NSCLC. A prospective study of genetic profiling of patients with lung cancer is currently underway that we hope will shed more light on this important issue.
